

Alessandra Tucci

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/8642418/alessandra-tucci-publications-by-year.pdf>

Version: 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

107
papers

3,975
citations

35
h-index

62
g-index

117
ext. papers

4,731
ext. citations

4.4
avg, IF

4.39
L-index

#	Paper	IF	Citations
107	Preneoplastic somatic mutations including in lymphoplasmacytic lymphoma.. <i>Science Advances</i> , 2022 , 8, eabl4644	14.3	4
106	Genetic and Phenotypic Attributes of Splenic Marginal Zone Lymphoma. <i>Blood</i> , 2021 ,	2.2	5
105	Response-Adapted Postinduction Strategy in Patients With Advanced-Stage Follicular Lymphoma: The FOLL12 Study. <i>Journal of Clinical Oncology</i> , 2021 , JCO2101234	2.2	7
104	Simplified Geriatric Assessment in Older Patients With Diffuse Large B-Cell Lymphoma: The Prospective Elderly Project of the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2021 , 39, 1214-1222	2.2	21
103	Clinical and prognostic role of sarcopenia in elderly patients with classical Hodgkin lymphoma: a multicentre experience. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021 , 12, 1042-1055	10.3	3
102	Comparison between skeletal muscle and adipose tissue measurements with high-dose CT and low-dose attenuation correction CT of F-FDG PET/CT in elderly Hodgkin lymphoma patients: a two-centre validation. <i>British Journal of Radiology</i> , 2021 , 94, 20200672	3.4	2
101	A brief rituximab, bendamustine, mitoxantrone (R-BM) induction followed by rituximab consolidation in elderly patients with advanced follicular lymphoma: a phase II study by the Fondazione Italiana Linfomi (FIL). <i>British Journal of Haematology</i> , 2021 , 193, 280-289	4.5	3
100	Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab. <i>Blood Cancer Journal</i> , 2021 , 11, 151	7	7
99	An increase in copy number has a progressive negative prognostic impact in patients with diffuse large B-cell and high-grade lymphoma, who may benefit from intensified treatment regimens. <i>Haematologica</i> , 2020 , 105, 1369-1378	6.6	9
98	Transplant eligibility in elderly multiple myeloma patients: Prospective external validation of the international myeloma working group frailty score and comparison with clinical judgment and other comorbidity scores in unselected patients aged 65-75 years. <i>American Journal of Hematology</i> , 2020 , 95, 759-765	7.1	7
97	Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients. <i>Annals of Hematology</i> , 2020 , 99, 1321-1330	3	11
96	The classic prognostic factors in advanced Hodgkin@ lymphoma patients are losing their meaning at the time of Pet-guided treatments. <i>Annals of Hematology</i> , 2020 , 99, 277-282	3	5
95	Clinical characteristics and risk factors for mortality in hematologic patients affected by COVID-19. <i>Cancer</i> , 2020 , 126, 5069-5076	6.4	38
94	Clinical and prognostic role of interim 18F-FDG PET/CT in elderly Hodgkin lymphoma: a dual-center experience. <i>Leukemia and Lymphoma</i> , 2020 , 61, 3209-3216	1.9	2
93	Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi. <i>Journal of Geriatric Oncology</i> , 2020 , 11, 37-40	3.6	9
92	The e13a2 BCR-ABL transcript negatively affects sustained deep molecular response and the achievement of treatment-free remission in patients with chronic myeloid leukemia who receive tyrosine kinase inhibitors. <i>Cancer</i> , 2019 , 125, 1674-1682	6.4	30
91	RESPONSE ORIENTED MAINTENANCE THERAPY IN ADVANCED FOLLICULAR LYMPHOMA. RESULTS OF THE INTERIM ANALYSIS OF THE FOLL12 TRIAL CONDUCTED BY THE FONDAZIONE ITALIANA LINFOMI.. <i>Hematological Oncology</i> , 2019 , 37, 153-154	1.3	14

90	Diagnostic and Clinical Impact of Staging F-FDG PET/CT in Mantle-Cell Lymphoma: A Two-Center Experience. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019 , 19, e457-e464	2	7
89	Prolonged survival in the absence of disease-recurrence in advanced-stage follicular lymphoma following chemo-immunotherapy: 13-year update of the prospective, multicenter randomized GITMO-IIL trial. <i>Haematologica</i> , 2019 , 104, 2241-2248	6.6	6
88	Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 449-458	2.5	33
87	Serum levels of polychlorinated biphenyls and risk of non-Hodgkin lymphoma: A hospital-based case-control study. <i>Chemosphere</i> , 2019 , 235, 969-975	8.4	4
86	Bleomycin, vinblastine and dacarbazine combined with nonpegylated liposomal doxorubicin (MBVD) in elderly (≥70 years) or cardiopathic patients with Hodgkin lymphoma: a phase-II study from Fondazione Italiana Linfomi (FIL). <i>Leukemia and Lymphoma</i> , 2019 , 60, 2890-2898	1.9	5
85	Prognostic role of MTV and TLG in Burkitt lymphoma. <i>Annals of Nuclear Medicine</i> , 2019 , 33, 280-287	2.5	7
84	Follicular lymphomas in vulnerable/older patients. <i>Current Opinion in Oncology</i> , 2019 , 31, 380-385	4.2	1
83	Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial. <i>Lancet, The</i> , 2019 , 394, 2271-2281	4.0	85
82	Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma. <i>Leukemia</i> , 2019 , 33, 1047-1051	10.7	12
81	Prognostic role of baseline F-FDG PET/CT parameters in MALT lymphoma. <i>Hematological Oncology</i> , 2019 , 37, 39-46	1.3	24
80	Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in Burkitt lymphoma. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2019 , 46, 87-96	8.8	40
79	Single-agent panobinostat for relapsed/refractory diffuse large B-cell lymphoma: clinical outcome and correlation with genomic data. A phase 2 study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2018 , 59, 2904-2910	1.9	5
78	Nonpegylated liposomal doxorubicin combination regimen in patients with diffuse large B-cell lymphoma and cardiac comorbidity. Results of the HEART01 phase II trial conducted by the Fondazione Italiana Linfomi. <i>Hematological Oncology</i> , 2018 , 36, 68-75	1.3	20
77	slan Monocytes and Macrophages Mediate CD20-Dependent B-cell Lymphoma Elimination via ADCC and ADCP. <i>Cancer Research</i> , 2018 , 78, 3544-3559	10.1	17
76	Primary cutaneous non-Hodgkin lymphoma: results of a retrospective analysis in the light of the recent ILROG guidelines. <i>Tumori</i> , 2018 , 104, 394-400	1.7	2
75	Long-Term Results of the FOLL05 Trial Comparing R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Symptomatic Follicular Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 689-696	2.2	81
74	Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials. <i>Blood Cancer Journal</i> , 2018 , 8, 108	7	22
73	Still a role for surgery as first-line therapy of splenic marginal zone lymphoma? Results of a prospective observational study. <i>International Journal of Surgery</i> , 2017 , 41, 143-149	7.5	5

72	Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. <i>Lancet Haematology, the</i> , 2017 , 4, e510-e523	14.6	157
71	Final Results of the IELSG-19 Randomized Trial of Mucosa-Associated Lymphoid Tissue Lymphoma: Improved Event-Free and Progression-Free Survival With Rituximab Plus Chlorambucil Versus Either Chlorambucil or Rituximab Monotherapy. <i>Journal of Clinical Oncology</i> , 2017 , 35, 1905-1912	2.2	98
70	Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study. <i>Lancet Oncology, The</i> , 2017 , 18, 1076-1088	21.7	72
69	A phase II study of bendamustine in combination with rituximab as initial treatment for patients with indolent non-follicular non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 880-7	1.9	8
68	Peri-operative complications and hematologic improvement after first-line splenectomy for splenic marginal zone lymphoma. <i>Leukemia and Lymphoma</i> , 2016 , 57, 1467-70	1.9	9
67	Alternative options for elderly patients with limited stage diffuse large B-cell lymphoma: R-chemotherapy vs. R-chemotherapy plus radiotherapy. <i>Leukemia and Lymphoma</i> , 2016 , 57, 2677-80	1.9	1
66	Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. <i>Lancet Haematology, the</i> , 2016 , 3, e217-27	14.6	288
65	The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study. <i>Haematologica</i> , 2015 , 100, 517-24	6.6	4
64	Comprehensive geriatric assessment is an essential tool to support treatment decisions in elderly patients with diffuse large B-cell lymphoma: a prospective multicenter evaluation in 173 patients by the Lymphoma Italian Foundation (FIL). <i>Leukemia and Lymphoma</i> , 2015 , 56, 921-6	1.9	90
63	The more patients you treat, the more you cure: managing cardiotoxicity in the treatment of aggressive non-Hodgkin lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 12-25	1.9	8
62	Autologous stem cell transplantation with in vivo purged progenitor cells shows long-term efficacy in relapsed/refractory follicular lymphoma. <i>American Journal of Hematology</i> , 2015 , 90, 230-4	7.1	8
61	The use of anthracycline at first-line compared to alkylating agents or nucleoside analogs improves the outcome of salvage treatments after relapse in follicular lymphoma The REFOLL study by the Fondazione Italiana Linfomi. <i>American Journal of Hematology</i> , 2015 , 90, 56-61	7.1	3
60	The Combination of Weekly Infusion of Rituximab and Bortezomib Is Effective in Relapsed or Refractory Indolent and Mantle Cell Lymphoma: Long-Term Results of Phase II BRIL06 Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2015 , 126, 2735-2735	2.2	2
59	Lenalidomide Maintenance Significantly Improves Progression-Free Survival (PFS) in Patients with Chemosensitive Relapse of Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Not Eligible for Autologous Stem Cell Transplantation (ASCT) or Experienced Relapse after Transplantation: Results of a Multicentre Phase II Trial. <i>Blood</i> , 2015 , 126, 1547-1547	2.2	0
58	Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. <i>Annals of Oncology</i> , 2014 , 25, 1404-1410	10.3	114
57	Analysis of 339 pregnancies in 181 women with 13 different forms of inherited thrombocytopenia. <i>Haematologica</i> , 2014 , 99, 1387-94	6.6	52
56	Outcome of frail elderly patients with diffuse large B-cell lymphoma prospectively identified by Comprehensive Geriatric Assessment: results from a study of the Fondazione Italiana Linfomi. <i>Leukemia and Lymphoma</i> , 2014 , 55, 38-43	1.9	54
55	Minimal residual disease after conventional treatment significantly impacts on progression-free survival of patients with follicular lymphoma: the FIL FOLL05 trial. <i>Clinical Cancer Research</i> , 2014 , 20, 6398-405	12.9	69

54	Panobinostat As Salvage Treatment for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Not Eligible to High Dose Therapy: A Phase II Study of the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2014 , 124, 1755-1755	2.2	2
53	R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 1506-13	2.2	193
52	Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi. <i>Journal of Clinical Oncology</i> , 2013 , 31, 3351-9	2.2	48
51	Lenalidomide plus cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab is safe and effective in untreated, elderly patients with diffuse large B-cell lymphoma: a phase I study by the Fondazione Italiana Linfomi. <i>Haematologica</i> , 2013 , 98, 1732-8	6.6	48
50	Inhibition Of Histone Deacetylases With Panobinostat As a Treatment For Relapsed Or Refractory Diffuse Large B-Cell Lymphoma: A Phase II Study By The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 3047-3047	2.2	2
49	Bendamustine and Rituximab Combination In Untreated Indolent Non Follicular B-Cell Non-Hodgkin Lymphomas. A Phase II Study From The Fondazione Italiana Linfomi (INFL09). <i>Blood</i> , 2013 , 122, 3049-3049	2.2	1
48	The Role Of Qualitative FDG-PET Assessment Using The 5 Point Deauville Scale For Postinduction Response Assessment In Patients With Follicular Lymphoma. A Study From The Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2013 , 122, 4295-4295	2.2	1
47	Prolonged Survival Of Poor Risk Follicular Lymphoma Patients Following Primary Treatment With Rituximab-Supplemented CHOP Or HDS With Autograft: Long-Term Results Of The Multicenter Randomized GITMO/FIL Trial. <i>Blood</i> , 2013 , 122, 551-551	2.2	3
46	Final Results Of Phase II Study Of Lenalidomide Plus Rituximab-CHOP21 In Elderly Untreated Diffuse Large B-Cell Lymphoma Focusing On The Analysis Of Cell Of Origin: REAL07 Trial Of The Fondazione Italiana Linfomi. <i>Blood</i> , 2013 , 122, 850-850	2.2	3
45	Salvage treatment with lenalidomide and dexamethasone in relapsed/refractory mantle cell lymphoma: clinical results and effects on microenvironment and neo-angiogenic biomarkers. <i>Haematologica</i> , 2012 , 97, 416-22	6.6	58
44	Palliative chemotherapy is not the best choice. <i>Journal of Geriatric Oncology</i> , 2012 , 3, S18	3.6	
43	Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano di Farmacoterapia Oncologica. <i>Journal of Clinical Oncology</i> , 2012 , 30, 501-8	1.9	56
42	Clinical and molecular characterization of diffuse large B-cell lymphomas with 13q14.3 deletion. <i>Annals of Oncology</i> , 2012 , 23, 729-735	10.3	17
41	Minimal Residual Disease Evaluated As Bcl2/Igh Rearrangement After Conventional Treatment Does Significantly Impact On Progression-Free Survival of Patients Affected by Follicular Lymphoma: The Experience of the Ancillary Trial Conducted by the Fondazione Italiana Linfomi (FIL). <i>Blood</i> , 2012 , 120, 3653-3653	2.2	
40	Genome-wide DNA profiling of marginal zone lymphomas identifies subtype-specific lesions with an impact on the clinical outcome. <i>Blood</i> , 2011 , 117, 1595-604	2.2	145
39	Continuous oral cyclophosphamide and prednisolone as a valuable treatment option for peripheral T cell lymphoma. <i>British Journal of Haematology</i> , 2011 , 152, 113-6	4.5	3
38	Integrated profiling of diffuse large B-cell lymphoma with 7q gain. <i>British Journal of Haematology</i> , 2011 , 153, 499-503	4.5	11
37	Diffuse large B-cell lymphoma with concordant bone marrow involvement has peculiar genomic profile and poor clinical outcome. <i>Hematological Oncology</i> , 2011 , 29, 38-41	1.3	23

36	Prevalence of <i>Borrelia burgdorferi</i> infection in a series of 98 primary cutaneous lymphomas. <i>Oncologist</i> , 2011 , 16, 1582-8	5.7	50
35	Brief Chemoimmunotherapy R-FND with Rituximab Consolidation Followed by Randomization Between Rituximab Maintenance Vs. Observation As First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Final Results of a Prospective Randomized Trial by Italian Lymphoma Foundation (IL). <i>Blood</i> , 2011 , 118, 777-777	2.2	4
34	Genomic lesions associated with a different clinical outcome in diffuse large B-Cell lymphoma treated with R-CHOP-21. <i>British Journal of Haematology</i> , 2010 , 151, 221-31	4.5	45
33	Immunogenetics features and genomic lesions in splenic marginal zone lymphoma. <i>British Journal of Haematology</i> , 2010 , 151, 435-9	4.5	15
32	Phase II trial of short-course R-CHOP followed by 90Y-ibritumomab tiuxetan in previously untreated high-risk elderly diffuse large B-cell lymphoma patients. <i>Clinical Cancer Research</i> , 2010 , 16, 3998-4004	12.9	51
31	Stereotyped patterns of B-cell receptor in splenic marginal zone lymphoma. <i>Haematologica</i> , 2010 , 95, 1792-6	6.6	74
30	Chlorambucil Plus Rituximab Produces Better Event-Free Survival in Comparison with Chlorambucil Alone in the Treatment of MALT Lymphoma: 5-Year Analysis of the 2-Arms Part of the IELSG-19 Randomized Study. <i>Blood</i> , 2010 , 116, 432-432	2.2	5
29	Salvage Treatment with Lenalidomide and Dexamethasone In Patients with Relapsed Refractory Mantle Cell Lymphoma: Clinical Results and Modifications of Angiogenic Biomarkers. <i>Blood</i> , 2010 , 116, 966-966	2.2	3
28	Association of Hodgkin Lymphoma and Non-Hodgkin Lymphoma In the Same Patient. Clinicopathologic Characteristics and Outcome In a Series of 20 Cases. <i>Blood</i> , 2010 , 116, 3886-3886	2.2	
27	A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. <i>Cancer</i> , 2009 , 115, 4547-53	6.4	200
26	Dose-dense and high-dose chemotherapy plus rituximab with autologous stem cell transplantation for primary treatment of diffuse large B-cell lymphoma with a poor prognosis: a phase II multicenter study. <i>Haematologica</i> , 2009 , 94, 1250-8	6.6	56
25	Long-Term Outcome of 309 Young Patients Affected by Diffuse Large B-Cell Lymphoma (DLBCL) with a Poor-Prognosis at Diagnosis: a Pooled Analysis From Four Consecutive Trials of GIMURELL and Italian Lymphoma Intergroup (IIL).. <i>Blood</i> , 2009 , 114, 2316-2316	2.2	
24	Late computed tomography scan response improvement and gallium scintigraphy evaluation as on-treatment prognostic parameters to tailor treatment intensity in patients with Hodgkin's lymphoma. A prospective phase II study. <i>Annals of Oncology</i> , 2008 , 19, 951-7	10.3	1
23	Immunochemotherapy with in vivo purging and autotransplant induces long clinical and molecular remission in advanced relapsed and refractory follicular lymphoma. <i>Annals of Oncology</i> , 2008 , 19, 1331-1333	10.3	35
22	Secondary acute lymphoblastic leukaemia following oxaliplatin for adjuvant chemotherapy in colon cancer. <i>Acta Oncologica</i> , 2008 , 47, 464-6	3.2	5
21	Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. <i>Blood</i> , 2008 , 111, 4331-4331	2.2	200
20	Brief Chemoimmunotherapy Rituximab (R)-FND □ R Maintenance as First Line Treatment in Elderly Patients with Advanced Follicular Lymphoma (FL): Preliminary Analysis of a Prospective Randomized IIL Trial. <i>Blood</i> , 2008 , 112, 834-834	2.2	1
19	Array-CGH Identifies Regions, Including the FOXP1 Locus, Associated with Different Clinical Outcome in Diffuse Large B-Cell Lymphomas (DLBCL) Treated with R-CHOP. <i>Blood</i> , 2008 , 112, 478-478	2.2	

18	Rituximab in combination with fludarabine and cyclophosphamide in the treatment of patients with recurrent follicular lymphoma. <i>Cancer</i> , 2007 , 110, 121-8	6.4	39
17	Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. <i>Blood</i> , 2007 , 110, 2316-23	2.2	260
16	Front-Line Brief Chemo-Immunotherapy Rituximab (R)-FND + Rituximab Consolidation □ Rituximab Maintenance in Elderly Patients with Untreated Advanced Stage Follicular Lymphoma (FL): First Interim Analysis of a Prospective Randomized Study (ML17638). <i>Blood</i> , 2007 , 110, 1278-1278	2.2	1
15	Delayed-onset peripheral blood cytopenia after rituximab: frequency and risk factor assessment in a consecutive series of 77 treatments. <i>Leukemia and Lymphoma</i> , 2006 , 47, 1013-7	1.9	112
14	Splenic marginal zone lymphoma: a prognostic model for clinical use. <i>Blood</i> , 2006 , 107, 4643-9	2.2	177
13	Oral cavity lymphomas in immunocompetent and human immunodeficiency virus infected patients. <i>Leukemia and Lymphoma</i> , 2005 , 46, 77-81	1.9	38
12	Effect of Adding Rituximab (R) to Induction Treatment and High Dose Chemotherapy (HDC) Prior to Autologous Stem Cell Transplantation (ASCT) as First Line Therapy in Stage III-IV Diffuse Large B-Cell Lymphoma (B-DLCL) at Poor Prognosis.. <i>Blood</i> , 2005 , 106, 676-676	2.2	
11	Fludarabine plus mitoxantrone with and without rituximab versus CHOP with and without rituximab as front-line treatment for patients with follicular lymphoma. <i>Journal of Clinical Oncology</i> , 2004 , 22, 2654-61	2.2	123
10	Transformation of a MGUS to overt multiple myeloma: the possible role of a pituitary macroadenoma secreting high levels of insulin-like growth factor 1 (IGF-1). <i>Leukemia and Lymphoma</i> , 2003 , 44, 543-5	1.9	15
9	Outbreak of Hepatitis C Virus Infection in Patients With Hematologic Disorders Treated With Intravenous Immunoglobulins: Different Prognosis According to the Immune Status. <i>Blood</i> , 1997 , 90, 1309-1314	2.2	39
8	A case of hypereosinophilic syndrome is associated with the expansion of a CD3-CD4+ T-cell population able to secrete large amounts of interleukin-5. <i>Blood</i> , 1996 , 87, 1416-1422	2.2	90
7	In Vitro Function of Peripheral Blood and Peritoneal B Lymphocytes from Capd Patientsa. <i>Peritoneal Dialysis International</i> , 1994 , 14, 84-86	2.8	
6	Occurrence of a silencer of the interleukin-2 gene in naive but not in memory resting T helper lymphocytes. <i>European Journal of Immunology</i> , 1993 , 23, 1469-74	6.1	24
5	Normal and atopic IgE responses. <i>Seminars in Immunopathology</i> , 1993 , 15, 29-36		
4	Historical perspectives of collagen diseases. <i>Clinics in Dermatology</i> , 1992 , 10, 393-7	3	2
3	Self tolerance to human A and B histo-blood group antigens exists at the B cell level and cannot be broken by potent polyclonal B cell activation in vitro. <i>European Journal of Immunology</i> , 1992 , 22, 2713-7	6.1	31
2	Effects of eleven cytokines and of IL-1 and tumor necrosis factor inhibitors in a human B cell assay. <i>Journal of Immunology</i> , 1992 , 148, 2778-84	5.3	27
1	Are cord blood B cells functionally mature?. <i>Clinical and Experimental Immunology</i> , 1991 , 84, 389-94	6.2	43

